Welcome to our dedicated page for ClearPoint Neuro SEC filings (Ticker: CLPT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ClearPoint Neuro, Inc. filings document the company's medical-device and therapy-enabling business, including operating results for its brain and spine navigation platforms, CNS drug-delivery services, and neurocritical-care portfolio after the completed IRRAS Holdings acquisition. Form 8-K reports furnish quarterly and annual results, Regulation FD investor presentations, acquisition-related financial statements, pro forma combined financial information, and material-event disclosures.
Proxy materials cover governance matters, director voting, executive compensation, pay-versus-performance data, and equity-award disclosures. The filing record also includes material agreements, capital-structure disclosure, shareholder voting matters, and clinical or regulatory disclosures tied to the company's regulated neurosurgical products and partnered biologics programs.
ClearPoint Neuro, Inc. CEO and President Joseph Burnett settled 84,829 restricted stock units, receiving the same number of common shares upon vesting. To cover tax withholding obligations, 43,161 common shares were delivered back to ClearPoint Neuro at $11.53 per share, which is not an open-market sale. Following these transactions, Burnett holds 95,900 common shares directly and an additional 193,231 common shares indirectly through the Joseph M. Burnett Trust dated 10/20/2022, where he serves as trustee.
ClearPoint Neuro, Inc. Chief Business Officer L. Jeremy Stigall settled restricted stock units into common shares as part of scheduled vesting. Each unit converts into one share of common stock, and this transaction reflects the routine exercise or conversion of 30,995 restricted stock units.
In connection with the vesting, 15,151 shares of common stock were delivered back to ClearPoint Neuro at $11.53 per share to satisfy tax withholding obligations, rather than being sold in the open market. After these transactions, Stigall directly holds 108,482 shares of common stock.
ClearPoint Neuro, Inc. Chief Operating Officer Sabra Mazin exercised and settled 26,101 restricted stock units into the same number of shares of common stock on their scheduled vesting date. Each unit represented a right to receive one share of common stock.
To cover tax withholding obligations tied to this vesting, 13,281 common shares were delivered back to ClearPoint Neuro at 11.5300 per share, a non-market, tax-withholding disposition rather than an open-market sale. After these transactions, Mazin directly holds 67,343 shares of common stock.
ClearPoint Neuro, Inc. Schedule 13G shows that MAK Capital Fund LP, MAK Capital One L.L.C. and Michael A. Kaufman beneficially own 1,729,611 shares of Common Stock, representing 6.1% of the class as of 03/13/2026. The filing reports shared voting and dispositive power over those shares. The excerpt cites 28,423,308 shares outstanding as of October 27, 2025 per the issuer's Form 10-Q.
ClearPoint Neuro, Inc.’s Chief Financial Officer Danilo D’Alessandro reported routine equity compensation activity involving restricted stock units. On March 11, 2026, 4,145 restricted stock units settled into the same number of common shares at a stated price of $0.00 per share, reflecting non-cash vesting.
In connection with this vesting, 2,109 common shares were delivered back to ClearPoint Neuro at $11.62 per share to satisfy tax withholding obligations, not as an open-market sale. After these transactions, D’Alessandro directly held 86,658 shares of common stock.
ClearPoint Neuro Chief Business Officer L. Jeremy Stigall settled restricted stock units into common shares. He exercised 8,291 restricted stock units into 8,291 shares of common stock. Of these, 3,224 shares at $11.62 per share were delivered back to ClearPoint Neuro to cover tax withholding, leaving him with 92,638 common shares held directly after the transactions.
ClearPoint Neuro CEO Joseph Burnett reported routine equity compensation activity. On March 6, 2026, 47,407 restricted stock units converted into the same number of shares of common stock at a stated price of $0.00 per share, reflecting scheduled vesting.
To cover tax obligations from this vesting, 22,709 common shares were delivered back to ClearPoint Neuro at $10.00 per share, a tax-withholding disposition rather than an open-market sale. After these transactions, Burnett directly holds 54,232 common shares and indirectly holds 193,231 common shares through the Joseph M. Burnett Trust dated October 20, 2022.
ClearPoint Neuro Chief Business Officer Jeremy L. Stigall settled previously granted equity awards into common shares and had part withheld for taxes. On 2026-03-06, he exercised 17,778 restricted stock units, receiving the same number of ClearPoint Neuro common shares at an exercise price of $0.00 per share.
To cover tax obligations tied to this vesting, 6,913 common shares were delivered back to ClearPoint Neuro at $10.00 per share as a tax-withholding disposition, rather than an open-market sale. After these transactions, Stigall directly owned 87,571 common shares of ClearPoint Neuro.
ClearPoint Neuro, Inc. Chief Operating Officer Sabra Mazin settled previously granted restricted stock units into 13,827 shares of common stock on their scheduled vesting date. To cover tax withholding obligations, 7,036 shares were delivered back to ClearPoint Neuro. Following these compensation-related transactions, Mazin directly holds 54,523 shares of common stock.
ClearPoint Neuro, Inc.’s Chief Financial Officer Danilo D’Alessandro reported routine equity compensation activity. He exercised 18,765 restricted stock units, converting them into the same number of common shares at a stated price of $0.00 per share as part of a scheduled vesting.
To cover tax obligations from this vesting, 9,548 common shares were delivered back to ClearPoint Neuro at $10.00 per share, classified as a tax-withholding disposition rather than an open-market sale. After these transactions, D’Alessandro directly holds 84,622 common shares of ClearPoint Neuro.